Thera-SAbDab

POGALIZUMAB

>   Structural Summary
TherapeuticPogalizumab
TargetTNFRSF4
Heavy ChainEVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQGLEWIGDMYPDNGDSSYNQKFRERVTITRDTSTSTAYLELSSLRSEDTAVYYCVLAPRWYFSVWGQGTLVTVSS
Light ChainDIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGHTLPPTFGQGTKVEIK
100% seqID Fv Structure6ogx [Fvs: CD], 6okn [Fvs: AB, CB]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Phase-II
Estimated Status (June '19)Discontinued
Recorded Developmental Technologyna
INN Year Proposed2015
INN Year Recommended2017
Companies InvolvedGenentech
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedSolid tumours, Urogenital cancer
NotesVonlerolizumab and Pogalizumab are the same mAb

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]